Sorin Visanica

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine

Raphaël Itzykson, Sylvain Thépot, Bruno Quesnel et al. · Blood · 2010 · 386 citations · Full text

Medicine, Oncology, Pharmacology +10

PICALM–MLLT10 acute myeloid leukemia: A French cohort of 18 patients

Cécile Borel, Nicole Dastugue, V. Cances-Lauwers et al. · Leukemia Research · 2012 · 56 citations

Medicine, Hematology, Oncology +5

The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience

Mathilde Lamarque, Sophie Raynaud, Raphaël Itzykson et al. · Blood · 2012 · 52 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +2

Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies

Lionel Adès, Fabien Le Bras, Marie Sébert et al. · Haematologica · 2011 · 44 citations · Full text

Medicine, Hematology, Pharmacotherapy +16

Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion—The GFM experience

Fabien Le Bras, Marie Sébert, Charikleia Kelaïdi et al. · Leukemia Research · 2011 · 39 citations

Medicine, Hematology, Oncology +12